Latest Intelligence on Pharmaceuticals and Healthcare in China

Published within

« | 1 | 2 | » »|

Type Product title / description Pub Price
Expert View
Expert View

APA 2011: advances and challenges in developing psychiatric services in China

With patents of several psychiatric drugs set to expire in the US and EU over 2011-12, key players are increasingly seeking to expand their geographical reach to growth markets in an attempt to extend revenue streams. In apparent recognition of this trend, the 164th Annual Meeting of the American Psychiatric Association included a forum dedicated to Chinese psychiatric services and research.

Published By Datamonitor
27 May 2011
Expert View
Expert View

Are the US and emerging markets ready for the generic drug boom?

One of Barack Obama's key goals as president is to reduce healthcare costs, particularly those related to prescription medications, by increasing the importation of generic drugs. However, the majority of these, or their ingredients, are manufactured in China, and to build confidence in such products, which are often considered unsafe, the FDA will require updated IT systems and solutions.

Published By Datamonitor
17 Nov 2008
CommentWire
CommentWire

Baxter: under fire over contaminated heparin

Already the subject of criticism over the withdrawal of its Chinese-made blood thinner heparin, Baxter International has now been accused of failing to co-operate with Chinese authorities trying to investigate the alleged contamination. The fallout of this saga could yet hold implications for other drug makers looking to gain benefit from low cost manufacturing countries such as China.

Published By Datamonitor
07 May 2008
Expert View
Expert View

Big Pharma rushing for foothold in emerging markets despite challenges

Faced with dwindling growth rates in the US and Europe, drug companies are turning their attention towards emerging pharmaceutical markets where recent economic booms have fuelled double-digit growth. However, although the patient potential of these countries is enormous, foreign pharmaceutical companies are currently tapping into only a fraction of the market.

Published By Datamonitor
13 Mar 2008
CommentWire
CommentWire

Boehringer Ingelheim: free antivirals for developing countries

Published By Datamonitor
05 Dec 2000
Expert View
Expert View

China: hepatitis treatment fails to keep pace with economy

According to a statement recently made by a senior health official in China, improvements in disease management and prevention have helped to transform infectious disease healthcare in China. However, there is still a considerable distance to go before China's healthcare system reaches western standards.

Published By Datamonitor
07 Feb 2006
CommentWire
CommentWire

Idenix/Novartis: filing for hepatitis hope

Idenix/Novartis have filed for FDA approval of their antiviral telbivudine. If approved, the drug candidate would become the fourth nucleoside reverse transcriptase inhibitor available to treat hepatitis B in the US. A strong efficacy and safety profile should ensure robust sales for the product, although it is set to face stiff competition in various markets.

Published By Datamonitor
04 Jan 2006
CommentWire
CommentWire

India: drug seizures dispute settled but concern remains over new trade agreement

The dispute between India and the European Union over recent seizures of Indian-made generics by a number of European countries has been settled before World Trade Organization action. However, Indian drug producers are growing increasingly concerned about the Anti-Counterfeiting Trade Agreement, and that it may allow seizures to become more commonplace.

Published By Datamonitor
12 Oct 2010
CommentWire
CommentWire

Novartis: strengthening vaccines presence in the lucrative Chinese market

Novartis has completed the acquisition of an 85% stake in the Chinese vaccines company Zhejiang Tianyuan Bio-Pharmaceuticals. Faced with limited growth opportunities in the Western markets, all major vaccines players are expanding activities into growth markets due to the high incidence of vaccine-preventable diseases and increasing public and private healthcare spending.

Published By Datamonitor
24 Mar 2011
CommentWire
CommentWire

Osteoarthritis: work and chopsticks identified as risk factors

Researchers in the US and China have found that even light repetitive movements, such as typing or using chopsticks, may increase the risk of osteoarthritis and other musculoskeletal diseases. Experts have been divided over whether repetitive tasks like typing can cause musculoskeletal damage, but this evidence suggests that daily tasks do indeed pose a risk.

Published By Datamonitor
14 Nov 2003

« | 1 | 2 | » »|

No help is available.